Eslicarbazepine acetate (ESL) is a voltage‐gated sodium and calcium channel blocker that
was identified as a promising candidate for clinical development in epilepsy through a drug …

Eslicarbazepine acetate (ESL) is a new antiepileptic drug whose mechanism of action is
blockade of the voltage-gated sodium channel (VGSC). However, in respect to …

Eslicarbazepine acetate (ESL) is a once-daily antiepileptic drug that is approved as
adjunctive therapy in adults with focal-onset seizures. Following oral administration, ESL is …

Epilepsy is a common chronic neurological condition affecting 50 million people worldwide.
Because at least 30% of patients with partial seizures do not achieve seizure control with the …

Epilepsy is a common neurological disorder. Despite a broad range of commonly used
antiepileptic drugs, approximately 30% of patients with epilepsy have drug resistance or …

Eslicarbazepine acetate, a novel antiepileptic agent, has recently been marketed as an
adjunctive therapy in adults with partial onset seizures with or without secondary …

Introduction: Eslicarbazepine acetate (ESL) is a third generation AED structurally related to
carbamazepine and oxcarbazepine, but without several of the drawbacks associated with …

Eslicarbazepine acetate (ESL) is a once daily new third generation antiepileptic drug that
shares the basic chemical structure of carbamazepine and oxcarbazepine–a dibenzazepine …

Eslicarbazepine acetate is an advanced antiseizure medication that is an improvement upon
carbamazepine and oxcarbazepine. This novel antiseizure medication regulates voltage …

Eslicarbazepine acetate (ESL) is a once daily antiepileptic drug (AED) approved by the
European Medicines Agency (EMA), the Food and Drug Administration (FDA) and Health …